Your search for apixaban returned 104 results

Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery

Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban

While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.

Apixaban is more effective than aspirin in reducing the risk of repeat stroke and systemic embolism in patients with atrial fibrillation (AF) who are unsuitable for vitamin K antagonists (VKA) therapy.

Improved communication with patients about cost, bleeding, and monitoring may increase compliance

The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.

Portola Pharmaceuticals, Bristol-Myers Squibb Company, and Pfizer announced results from the Phase 3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Apixaban) study with andexanet alfa as a reversal agent for Eliquis (apixaban).

Apixaban and rivaroxaban are both factor Xa inhibitors.

Lower rates seen for ischemic stroke or systemic embolism, GI bleeding or intracranial hemorrhage.

Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.